Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer

H H Hansen1, M Rørth

  • 1Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Combination chemotherapy is the standard for small cell lung cancer (SCLC), offering high response rates but limited long-term survival. For non-small cell lung cancer (NSCLC), cisplatin-based chemotherapy shows modest benefits, with new agents emerging.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

Animal : an international journal of animal bioscience·2020
Same author

Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

Tropical animal health and production·2017
Same author

High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

Endocrine regulations·2015
Same author

Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

Journal of dairy science·2014
Same author

Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

Developmental neuroscience·2010
Same author

The medullary nail presentation of a new type and report of a case.

Archives of surgery (Chicago, Ill. : 1920)·2010
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Combination chemotherapy, including etoposide, cisplatin, and carboplatin, forms the backbone of small cell lung cancer (SCLC) therapy.
  • Current SCLC treatments yield high response rates (80-90%) and median survival of 11-18 months, but 5-year survival remains low (around 5%).
  • For non-small cell lung cancer (NSCLC), cisplatin-containing chemotherapy offers a statistically significant, though small, advantage when combined with surgery or radiotherapy.

Purpose of the Study:

  • To review the current landscape of lung cancer chemotherapy, focusing on small cell and non-small cell lung cancer.
  • To evaluate the efficacy of established and novel chemotherapeutic agents and treatment strategies.
  • To discuss the clinical relevance, toxicity, and cost-effectiveness of different lung cancer treatment modalities.

Main Methods:

Related Experiment Videos

  • Review of meta-analyses and phase III trials in lung cancer treatment.
  • Analysis of response rates, duration of response, and survival data from clinical studies.
  • Evaluation of new chemotherapeutic agents like navelbine, topotecan, gemcitabine, and taxanes.

Main Results:

  • SCLC combination chemotherapy achieves high response rates (80-90%) with median survival of 11-18 months, but 5-year survival is poor (~5%).
  • Cisplatin-containing chemotherapy shows a significant benefit in NSCLC stages I-IV, particularly when combined with surgery or radiotherapy.
  • New agents like navelbine, topotecan, gemcitabine, and taxanes show encouraging results in both SCLC and NSCLC.

Conclusions:

  • Combination chemotherapy remains the standard for SCLC, but novel approaches are needed to improve long-term survival.
  • Cisplatin-based chemotherapy offers a survival advantage in NSCLC, with combined modality treatments showing promise.
  • Ongoing research into new agents and treatment strategies is crucial for advancing lung cancer therapy.